Asymptomatic Myeloma Prognosis
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- ——
- ——
- ——
The Asymptomatic Myeloma Prognosis calculates predicting risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis. Key inputs include bone marrow plasmacytosis. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis
Clinical Indication
The Asymptomatic Myeloma Prognosis is indicated for bedside clinical practice to support Predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.
Risk stratification based on bone marrow plasmacytosis percentage and serum monoclonal protein level: Low Risk (both <10% and <3 g/dL), Intermediate Risk (one factor present), High Risk (both ≥10% and ≥3 g/dL)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| bone_marrow_plasmacytosis | string | Yes | Average percentage from bone marrow aspirate and core biopsy(%) |
| serum_monoclonal_protein | string | Yes | Serum monoclonal protein level on serum protein electrophoresis(g/dL) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| — | — | Both bone marrow plasmacytosis <10% and serum M-protein <3 g/dL |
| — | — | Either bone marrow plasmacytosis ≥10% OR serum M-protein ≥3 g/dL (but not both) |
| — | — | Both bone marrow plasmacytosis ≥10% AND serum M-protein ≥3 g/dL |
Evidence-Based References (EBM)
- Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582-90.
- Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125(20):3069-75.
- Mateos MV, Kumar S, Dimopoulos MA, González-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102.